system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Antineoplastic Agents, Blotting, Western, Carcinoma, Adenoid Cystic, Cell Culture Techniques, Cell Line, Tumor, Cell Survival, Coloring Agents, Dose-Response Relationship, Drug, Down-Regulation, Drugs, Chinese Herbal, Electrophoresis, Polyacrylamide Gel, Humans, I-kappa B Proteins, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, NF-kappa B, Naphthoquinones, Neoplasm Invasiveness, Tetrazolium Salts, Thiazoles, Time Factors, Tumor Necrosis Factor-alpha.
user
Does shikonin inhibit tumor invasion via down-regulation of NF-κB-mediated MMP-9 expression in human ACC-M cells? Context: The aim of this study was to examine the anti-invasion effect of Shikonin on human high-metastatic adenoid cystic carcinoma (ACC-M) cells and to explain the possible molecular mechanism involved. The ACC-M cells were treated with Shikonin (0, 2.5, 5, 10 μM) for 24 h. The protein levels and gelatinolytic activities of MMP-2 and MMP-9 were analyzed using Western blot and Gelatin zymography test, respectively. Matrigel invasion assays were used to investigate tumor invasive potential and electromobility shift assays were used to determine the activity of NF-κB. The invasiveness of ACC-M cells was reduced in a dose dependent manner following 24-h treatment of up to 10 μM of the Shikonin at which concentration no cytotoxicity occurred. The protein levels and gelatinolytic activities of MMP-9 were significantly suppressed by increasing Shikonin concentrations. The down-regulation of MMP-9 appeared to be via the inactivation of NF-κB as the treatment with Shikonin suppressed the protein level of phosphate-IkBa, which was accompanied by a decrease in DNA-binding level of the factor.
assistant
Shikonin inhibits tumor invasion via downregulation of MMP-9 expression in ACC-M cells. Pharmacologic inhibition of the NF-κB-mediated MMP-9 expression by Shikonin might be a powerful treatment option for ACC patients in future. Final Decision: yes